Skip to main content
Clinical Trials/NCT05753787
NCT05753787
Active, not recruiting
Not Applicable

Assessment of the Eye Surface and Subjective Symptoms After Using Dexamethasone Drops With and Without Preservatives in Patients After Cataract Surgery

Spektrum Center of Clinical Ophthalmology1 site in 1 country40 target enrollmentJanuary 1, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cataract
Sponsor
Spektrum Center of Clinical Ophthalmology
Enrollment
40
Locations
1
Primary Endpoint
Best corrected visual acuity result
Status
Active, not recruiting
Last Updated
2 years ago

Overview

Brief Summary

The goal of this interventional, real world data study is to evaluate the impact of preservatives on the post-cataract ocular surface.

The main question is to learn about an effect of preservatives on the eye surface. The study aims to answer some important questions:

  • if the usage of preservatives has an impact on the eye surface healing process after cataract surgery
  • if patient comfort and quality of life improve more or more rapidly with preservatives-free eye drops.

Participants will be asked to undergo standard procedure of peri-cataract surgery care and in addition to survey about the ocular surface state.

Researchers will compare group that takes preservatives-free dexamethasone 0.1% with standard dexamethasone 0.01% solution to see if post-surgery eye surface healing properties differ from both groups.

Registry
clinicaltrials.gov
Start Date
January 1, 2022
End Date
December 31, 2025
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Spektrum Center of Clinical Ophthalmology
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • cataract surgery required defined previously by the eye-care specialist
  • good and clear visibility of the anterior chamber in the pre-surgery status (enables investigators to assess the anterior chamber cell intensity)
  • consent to the study protocol

Exclusion Criteria

  • diagnosed glaucoma
  • diagnosed previous allergy
  • diagnosed diabetic retinopathy or maculopathy
  • previously diagnosed dry eye disease that requires treatment with multiple artificial tears
  • permanent usage of the eye drops other than artificial tears
  • non-compliance to the study protocol

Outcomes

Primary Outcomes

Best corrected visual acuity result

Time Frame: up to 21 days post-surgery

best corrected visual acuity evaluated with standard ETDRS for distant and for near vision

Ocular staining score result

Time Frame: up to 21 days post-surgery

standard staining score - a scale used with the fluorescein stain; higher value expres more severe outcome, normal values are around 0-1. Overal information can be found: https://entokey.com/a-simplified-quantitative-method-for-assessing-keratoconjunctivitis-sicca-from-the-sjogrens-syndrome-international-registry/

Ocular Surface Disease Index survey result

Time Frame: up to 21 days post-surgery

a standard survey that patient will preform at each visit

Secondary Outcomes

  • Shirmer test 1 measurement(up to 21 days post-surgery)
  • Intraocular pressure measurement(up to 21 days post-surgery)
  • Anterior chamber cell intensity measurement(up to 21 days post-surgery)
  • SICCA scale assessment(up to 21 days post-surgery)
  • Fluorescein Break-up Time assessment(up to 21 days post-surgery)

Study Sites (1)

Loading locations...

Similar Trials